IP Library Granted Patent US 11,426,388
Granted Patent B2
US 11,426,388 · App. 16/460,161 · Granted Aug 30, 2022

Controlled release pharmaceutical formulations of nitazoxanide

Inventors: Jean-Francois Rossignol (St. Petersburg, FL); Marc Ayers (Tampa, FL)
Assignee: Romark Laboratories L.C.
A61K31/426A61K9/209A61K9/2086A61K9/28A61K9/284A61K9/2853A61K9/4808A61K31/7056A61K38/21A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,426,388
App. No.
16/460,161
Granted
Aug 30, 2022
Kind
B2
Abstract

Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.

Claims (13)

1. A pharmaceutical composition in the form of a solid oral dosage form comprising:

(a) a first portion comprising a first quantity of nitazoxanide, tizoxanide or a combination thereof in a controlled release formulation; and

(b) a second portion comprising a second quantity of nitazoxanide, tizoxanide or a combination thereof in an immediate release formulation.

2. The composition of claim 1 , wherein the solid oral dosage form is a tablet.

3. The composition of claim 2 , wherein the first portion (a) forms a first layer of the tablet, and the second portion (b) forms a second layer deposited on top of the first layer (a).

4. The composition of claim 2 , wherein the first portion (a) forms a first layer of the tablet; the second portion (b) forms a second layer that is deposited on top of the first layer (a) to form a core tablet comprising the first layer and the second layer; and (c) an outer coating layer that is deposited on top of the core tablet.

5. The composition of claim 1 , wherein the solid oral dosage form is a capsule.

6. The composition of claim 1 , wherein the first portion further comprises one or more diluents, disintegrants, binders, suspending agents, glidants, lubricants, fillers, or additional excipients.

7. The composition of claim 6 , wherein the first portion further comprises hydroxypropylcellulose and hydroxypropylmethylcellulose as the binders, dicalciumphosphate dehydrate as the filler, colloidal anhydrous silica as the glidant, and magnesium stearate as the lubricant.

8. The composition of claim 1 , wherein the second portion further comprises one or more diluents, disintegrants, binders, suspending agents, glidants, lubricants, fillers, or additional excipients.

9. The composition of claim 8 , wherein the second portion further comprises hydroxypropylcellulose and microcrystalline cellulose as the binders, maize starch as the diluent, sodium croscarmellose as the disintegrant, colloidal anhydrous silica as the glidant, and magnesium stearate as the lubricant.

10. The composition of claim 1 , wherein the first portion further comprises a low viscosity polymer.

11. The composition of claim 10 , wherein the low viscosity polymer is a low viscosity hydroxypropyl-methylcellulose.

Assignments (1)
SECURITY INTEREST Recorded Nov 16, 2019
From: ROMARK BIOSCIENCES S.À R.L. LLC; ROMARK LABORATORIES, L.C.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 051030/0613 →